Skip to main content
. Author manuscript; available in PMC: 2013 May 16.
Published in final edited form as: Cell. 2013 Mar 28;153(1):71–85. doi: 10.1016/j.cell.2013.02.036

Figure 7. A model for reversible transformation by the SS18-SSX1 oncogenic fusion.

Figure 7

(A) (left) Anti-Brg IPs on 293T, B35, Aska-SS and Yamato-SS cells bearing introduced BAF47-V5; (middle) anti-V5 IPs; (right) Total protein inputs.

(B) Anti-Brg IPs on nuclear extracts of Aska-SS and Yamato-SS cells with stably introduced BAF47-V5 and co-infection with either control vector, SS18FL, or shSS18-SSX.

(C) Proliferation analyses of Aska-SS cells infected with either control vector, BAF47-V5, or BAF47-V5+co-infected SS18FL, BAF47-V5+co-infected shSS18-SSX. Error bars= s.d.

(D) Model for reversible disruption of BAF complex composition and action upon SS18-SSX incorporation.